SRT 2379
Alternative Names: SRT2379Latest Information Update: 02 Oct 2021
At a glance
- Originator Sirtris
- Developer GSK
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Netherlands (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in United Kingdom (PO, Capsule)
- 28 Feb 2011 Phase-I clinical trials in Inflammation in Netherlands (PO)